Congenital heart disease linked to maternal autoimmunity against cardiac myosin

Charles R Cole1, Katherine E Yutzey, Anoop K Brar

  • 1Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;

Insights

This study introduces a novel autoimmune model for congenital heart disease (CHD), specifically hypoplastic left heart syndrome (HLHS). It suggests maternal autoantibodies against cardiac myosin may cause prenatal HLHS in fetuses.

Area of Science:

  • Immunology
  • Cardiology
  • Developmental Biology

Background:

  • Structural congenital heart disease (CHD) lacks established links to autoimmunity.
  • Hypoplastic left heart syndrome (HLHS) is a severe left ventricular defect with unknown pathogenesis.
  • Cardiac myosin (CM) is a known autoantigen in autoimmune heart conditions.

Purpose of the Study:

  • To develop an autoimmune model of structural CHD resembling HLHS.
  • To investigate the role of maternal autoantibodies against CM in prenatal HLHS development.
  • To explore potential immune-mediated mechanisms in HLHS pathogenesis.

Main Methods:

  • Developed a maternal-fetal autoimmune model of CHD using CM immunization.
  • Assessed maternal and fetal serum autoantibody titers (anti-CM, anti-β-adrenergic receptor).
  • Examined IgG reactivity in fetal myocardium and cardiac protein kinase A activity.

Main Results:

  • Maternal immunization with CM induced anti-CM autoantibodies that crossed the placenta.
  • Elevated maternal and fetal anti-CM autoantibodies correlated with structural CHD and diminished left ventricular dimensions.
  • Fetuses with HLHS phenotype showed increased anti-β-adrenergic receptor Abs and protein kinase A activity.

Conclusions:

  • Presents the first evidence of an immune-mediated mechanism for structural CHD pathogenesis, specifically HLHS.
  • Suggests autoimmunity against CM may play a role in HLHS development via transplacental autoantibody transfer.
  • Highlights potential implications for future diagnosis and treatment of HLHS through an immune-mediated lens.

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
1.0K
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.4K
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
645
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
53
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
826